Compile Data Set for Download or QSAR
Report error Found 172 Enz. Inhib. hit(s) with all data for entry = 12212
TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687826(US20240246981, Example 54)
Affinity DataIC50: 0nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687832(US20240246981, Example 60)
Affinity DataIC50: 0nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687841(US20240246981, Example 69)
Affinity DataIC50: 0nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687841(US20240246981, Example 69)
Affinity DataIC50: 0nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687778(US20240246981, Example 6)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687791(US20240246981, Example 19)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687794(US20240246981, Example 22)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687802(US20240246981, Example 30)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM661126(US20240101544, Example 11 | 2-[4-(4-methyl-4H-1,2,...)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687805(US20240246981, Example 33)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687806(US20240246981, Example 34)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687808(US20240246981, Example 36)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687812(US20240246981, Example 40)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687822(US20240246981, Example 50)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687822(US20240246981, Example 50)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687825(US20240246981, Example 53)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687826(US20240246981, Example 54)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687827(US20240246981, Example 55)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687827(US20240246981, Example 55)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687828(US20240246981, Example 56)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687830(US20240246981, Example 58)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687830(US20240246981, Example 58)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687832(US20240246981, Example 60)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687833(US20240246981, Example 61)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687834(US20240246981, Example 62)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687834(US20240246981, Example 62)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687835(US20240246981, Example 63)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687843(US20240246981, Example 71)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687844(US20240246981, Example 72)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687844(US20240246981, Example 72)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687846(US20240246981, Example 74)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687846(US20240246981, Example 74)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687847(US20240246981, Example 75)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687847(US20240246981, Example 75)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687848(US20240246981, Example 76)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687853(US20240246981, Example 81)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687855(US20240246981, Example 83)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687858(US20240246981, Example 86)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687858(US20240246981, Example 86)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM661116(US20240101544, Example 1 | US20240101544, Example ...)
Affinity DataIC50: 2nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687775(US20240246981, Example 4)
Affinity DataIC50: 2nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687779(US20240246981, Example 7)
Affinity DataIC50: 2nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687800(US20240246981, Example 28)
Affinity DataIC50: 2nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687807(US20240246981, Example 35)
Affinity DataIC50: 2nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687808(US20240246981, Example 36)
Affinity DataIC50: 2nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687813(US20240246981, Example 41)
Affinity DataIC50: 2nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687818(US20240246981, Example 46)
Affinity DataIC50: 2nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687819(US20240246981, Example 47)
Affinity DataIC50: 2nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687821(US20240246981, Example 49)
Affinity DataIC50: 2nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687823(US20240246981, Example 51)
Affinity DataIC50: 2nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
Go to US Patent

Displayed 1 to 50 (of 172 total ) | Next | Last >>
Jump to: